8-K: Bionomics Completes Redomiciliation, Neuphoria Therapeutics Commences Trading on Nasdaq
Merger Announcement
Bionomics Limited has completed its redomiciliation to the United States, becoming a wholly-owned subsidiary of Neuphoria Therapeutics Inc., with Neuphoria shares commencing trading on Nasdaq.
Summary
- Bionomics Limited has completed its redomiciliation from Australia to the United States, becoming a wholly-owned subsidiary of Neuphoria Therapeutics Inc.
- Neuphoria shares commenced trading on Nasdaq under the ticker symbol NEUP on December 24, 2024, or as soon as possible thereafter.
- Bionomics shareholders received one Neuphoria share for every 2,160 Bionomics shares.
- Bionomics ADS holders received one Neuphoria share for every 12 Bionomics ADSs.
- Neuphoria will issue options to Bionomics option holders and a warrant to an institutional investor holding a Bionomics warrant.
- The redomiciliation was implemented through a scheme of arrangement under Australian law.
- Bionomics ADSs were suspended from trading on Nasdaq prior to the start of trading on the Effective Date.
Sentiment
Score: 8
Explanation: The document is positive, indicating a successful completion of a complex transaction and the commencement of trading on a major exchange. The tone is professional and forward-looking.
Positives
- The redomiciliation process was successfully completed.
- Neuphoria shares are now trading on Nasdaq, providing access to US capital markets.
- The exchange of shares and warrants was completed as planned.
Risks
- The document mentions forward-looking statements, which are subject to risks and uncertainties.
- The document notes that actual results may differ materially from those set forth in the release due to inherent business risks.
Future Outlook
Neuphoria shares are expected to commence trading on Nasdaq on December 24, 2024, or as soon as possible thereafter. The company will continue to develop therapies for neuropsychiatric disorders.
Management Comments
- Neuphoria is pleased to announce that its previously announced scheme of arrangement in relation to Bionomics Limiteds proposed re-domiciliation from Australia to the United States, under which Neuphoria will become the ultimate parent company of Bionomics Limited, has been implemented today, December 23, 2024 New York time (December 24, 2024 Sydney time).
Industry Context
This announcement reflects a trend of companies seeking to access larger capital markets by redomiciling to the US. It also highlights the ongoing activity in the biotechnology sector, with companies focused on developing new therapies for complex disorders.
Comparison to Industry Standards
- The redomiciliation process is similar to other cross-border transactions where companies seek to list on US exchanges for better access to capital.
- The share exchange ratio is specific to this transaction and is not directly comparable to other mergers or acquisitions.
- The listing on Nasdaq is a common goal for biotechnology companies seeking to raise capital and increase visibility.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| President, Chief Executive Officer and Director | NA | Spyros Papapetropoulos | December 23, 2024 | Redomiciliation |
| Chief Financial Officer | NA | Tim Cunningham | December 23, 2024 | Redomiciliation |
| Chair of the Board of Directors | NA | Alan Fisher | December 23, 2024 | Redomiciliation |
| Director | NA | Miles Davies | December 23, 2024 | Redomiciliation |
| Director | NA | Jane Ryan, Ph.D. | December 23, 2024 | Redomiciliation |
| Director | NA | David Wilson | December 23, 2024 | Redomiciliation |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Board Classification | The Board is divided into three classes with staggered three-year terms. | December 23, 2024 | Ensures continuity and makes it more difficult to change the composition of the board. |
| Board Committees | The Board has standing Audit and Compensation Committees. | December 23, 2024 | Establishes key governance structures. |
| Stock Incentive Plan | Neuphoria has adopted the 2024 Equity Incentive Plan. | December 23, 2024 | Provides a framework for equity-based compensation. |
| Indemnification Agreements | Neuphoria has entered into indemnification agreements with directors and executive officers. | December 23, 2024 | Provides protection against certain liabilities. |
| Articles of Incorporation and Bylaws | The rights of shareholders are now governed by Neuphorias Amended and Restated Certificate of Incorporation and Bylaws. | December 23, 2024 | Changes the legal framework governing shareholder rights. |
| Code of Conduct | Neuphoria has adopted a Code of Conduct applicable to all directors, officers and employees. | December 23, 2024 | Establishes ethical standards for the company. |
Stakeholder Impact
- Shareholders of Bionomics have become shareholders of Neuphoria.
- Bionomics option and warrant holders will receive Neuphoria options and warrants.
- Employees of Bionomics are now part of Neuphoria.
Next Steps
- Neuphoria shares will commence trading on Nasdaq.
- Neuphoria will issue options to Bionomics option holders.
- Neuphoria will issue a warrant to an institutional investor holding a Bionomics warrant.
Key Dates
| Date | Description |
|---|---|
| October 1, 2024 | Date of the original Scheme Implementation Agreement between Bionomics and Neuphoria. |
| October 3, 2024 | Date the Amended and Restated Certificate of Incorporation was filed with the Secretary of State of Delaware. |
| October 24, 2024 | Date of the Amending Agreement to the Scheme Implementation Agreement. |
| December 23, 2024 | Effective date of the redomiciliation and commencement of Neuphoria as the successor issuer. |
| December 24, 2024 | Expected date for Neuphoria shares to commence trading on Nasdaq. |
Keywords
redomiciliation, Neuphoria Therapeutics, Bionomics Limited, Nasdaq, scheme of arrangement, successor listing, share exchange, ADS, NEUP, BNOX
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.